|Videos|July 14, 2021

The Use of Clinical Endpoints in the ZUMA-3 Trial

Author(s)Eunice Wang, MD, Bijal D. Shah, MD

Bijal Shah, MD, MS, and Eunice Wang, MD, discussed the use of clinical endpoints like CR, CRi, and CRh as they relate to the ZUMA-3 trial of CAR T cell therapy.

This content originally appeared on our sister site, OncLive.

Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.

Related to this article

April 3rd, 2026

ImmunoLogic, Episode 9: "Rewiring Immunotherapy for High-Risk Neuroblastoma" With Kristopher R. Bosse, MD

In episode 9 of ImmunoLogic, Kristopher Bosse, MD, and the cohosts discussed how immunotherapy is reshaping treatment for high-risk neuroblastoma.

September 2nd, 2026

Novartis, BMS Pause Autoimmune CAR-T Trials After Safety Events

Novartis suspended several autoimmune and neurology trials of rap-cel after 3 patient deaths linked to immune effector cell-associated hemophagocytic syndrome, and BMS separately paused zola-cel studies after observing inflammatory safety events.

August 17th, 2026

J&J Secures $2.58B Option to Acquire Sail Biomedicines

Johnson & Johnson secures an exclusive option to acquire Sail Biomedicines for $2.58 billion, backing the biotech's in vivo CAR T platform for immune-mediated disease.